CytomX Therapeutics (CTMX) Depreciation & Amortization (CF) (2014 - 2026)
CytomX Therapeutics (CTMX) posted Depreciation & Amortization (CF) of $214000.0 for Q1 2026, down 54.76% on a QoQ basis from $473000.0 in Q4 2025, and down 38.68% year-over-year from $349000.0 in Q1 2025.
CytomX Therapeutics (CTMX) Depreciation & Amortization (CF) (2014 - 2026) Analysis & Trends
CytomX Therapeutics' Depreciation & Amortization (CF) history runs 13 years deep, the most recent figure standing at $214000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 38.68% year-over-year to $214000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 28.9% YoY) and the FY2025 annual result came in at $1.2 million, down 24.17% from the prior year.
- Depreciation & Amortization (CF) was $214000.0 for Q1 2026 at CytomX Therapeutics, down from $473000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $586000.0 in Q3 2022 and bottomed at $98000.0 in Q3 2025.
- A 5-year average of $434823.5 and a median of $448000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Peak annual rise in Depreciation & Amortization (CF) reached 25.8% in 2025, while the deepest fall reached 75.06% in 2025.
- CytomX Therapeutics' Depreciation & Amortization (CF) stood at $572000.0 in 2022, then fell by 21.5% to $449000.0 in 2023, then fell by 16.26% to $376000.0 in 2024, then rose by 25.8% to $473000.0 in 2025, then slumped by 54.76% to $214000.0 in 2026.
- Business Quant data shows CTMX's Depreciation & Amortization (CF) at $214000.0 in Q1 2026, $473000.0 in Q4 2025, and $98000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | CytomX Therapeutics | 590.32 Mn | 243.61 Mn | - | 214,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 214,000.00 |
| Mar 31, 2026 | 214,000.00 |
| Dec 31, 2025 | 473,000.00 |
| Dec 31, 2025 | 473,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Jun 30, 2025 | 310,000.00 |
| Jun 30, 2025 | 310,000.00 |
| Mar 31, 2025 | 349,000.00 |
| Mar 31, 2025 | 349,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Sep 30, 2024 | 393,000.00 |
| Sep 30, 2024 | 393,000.00 |
| Jun 30, 2024 | 422,000.00 |
| Jun 30, 2024 | 422,000.00 |
| Mar 31, 2024 | 431,000.00 |
| Mar 31, 2024 | 431,000.00 |
| Dec 31, 2023 | 449,000.00 |
| Dec 31, 2023 | 449,000.00 |